Carlsmed has initiated its initial public offering (IPO) roadshow, offering 6.7 million shares with an option for underwriters to purchase an additional 1 million shares. The company expects a price range of $14 to $16 per share, potentially raising over $123 million if priced at the high end.
Based in Carlsbad, California, Carlsmed develops AI-enabled personalized spine surgery technologies. Its Aprevo lumbar and cervical interbody fusion devices hold FDA breakthrough device designation, with several implantable devices and software cleared for lumbar spine fusion procedures.
The company plans to list on Nasdaq under the ticker “CARL.” BofA Securities, Goldman Sachs, and Piper Sandler lead the offering, with Truist Securities and BTIG as joint book-runners.
Follow MEDWIRE.AI for medtech IPO and innovation updates.
